Scientific Surgery Online Journals

This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS

Scientific Surgery

Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node–positive and high-risk lymph node–negative breast cancer (E5103). J Clin Oncol 2018; 36: 2621-2629.

Authors: Miller KD, O’Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA et al.

Scientific Surgery

Effects of celecoxib and low-dose aspirin on outcomes in adjuvant aromatase inhibitor–treated patients: CCTG MA.27. J Natl Cancer Inst 2018; 110: 1003–1008.

Authors: Strasser-Weippl K, Higgins MJ, Chapman J-AW, Ingle JN, Sledge GW, Budd GT et al.

Scientific Surgery

Prospective randomized trial of use of in-house prepared low-cost radiopharmaceutical versus commercial radiopharmaceutical for sentinel lymph node biopsy in patients with early stage invasive breast cancer. World J Surg 2018; 42: 1391-1395.

Authors: Agarwal G, Rajan S, Mayilvaganan S, Mishra A, Krishnani N, Gambhir S et al.

Scientific Surgery

Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018; 379:122-137.

Authors: Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I et al.

Scientific Surgery

Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018; 379:111-121.

Authors: Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF et al.

Scientific Surgery

Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst 2018; 110: 40-48.

Authors: Blok EJ, Kroep JR, Kranenbarg EM-K, Duijm-de Carpentier M, Putter H, van den Bosch J et al.

Scientific Surgery

De-escalation strategies in human epidermal growth factor receptor 2 (HER2)–positive early breast cancer (BC): final analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor–positive phase II randomized trial—efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET. J Clin Oncol 2017; 35: 3046-3054.

Authors: Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S et al.

Scientific Surgery

Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial. J Clin Oncol 2017; 35: 2639-2646.

Authors: Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen M-B, Knoop AS, Højris I et al.

Scientific Surgery

Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla – Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. EJSO 2017; 43: 672-679.

Authors: Sávolt A, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E et al.

Scientific Surgery

Intraoperative ultrasound guidance in breast-conserving surgery shows superiority in oncological outcome, long-term cosmetic and patient-reported outcomes: Final outcomes of a randomized controlled trial (COBALT). EJSO 2017; 43: 649-657.

Authors: Volders JH, Haloua MH, Krekel NMA, Negenborn VL, Kolk RHE, Lopes Cardozo AMF et al.

Scientific Surgery

Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis. The ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 2017; 318: 918-926.

Authors: Giuliano AG, Ballman KV, McCall L, Beitsch P, Brennan MB, Keleman PR et al.

Scientific Surgery

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 2017; 390: 1048–1060.

Authors: Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A et al.

Scientific Surgery

Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone-receptor positive, node-negative early breast cancer: final results of the randomized phase III Femara versus Anastrozole Clinical Evaluation (FACE) trial. J Clin Oncol 2017; 35: 1041-1048.

Authors: Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K et al.

Scientific Surgery

Effect of home monitoring via mobile app on the number of in-person visits following ambulatory surgery. A randomized clinical trial. JAMA Surg 2017; 152: 622-627.

Authors: Armstrong K, Coyte PC, Brown, M, Beber B, Semple JL

Scientific Surgery

Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor–positive, node-positive early breast cancer: final results of the randomized phase III Femara versus Anastrozole Clinical Evaluation (FACE) Trial. J Clin Oncol 2017; 35: 1041-1048.

Authors: Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K et al.

Scientific Surgery

Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017; 377: 122-131.

Authors: von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G et al.

Scientific Surgery

Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla – Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer. EJSO 2017; 43: 672-679.

Authors: Sávolt A, Péley A, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E et al.

Scientific Surgery

Intraoperative ultrasound guidance in breast-conserving surgery shows superiority in oncological outcome, long-term cosmetic and patient-reported outcomes. EJSO 2017; 43: 649-657.

Authors: Volders JH, Haloua MH, Krekel NMA, Negenborn VL, Kolk RHE, Lopes Cardozo AMF et al.

Scientific Surgery

Radioactive seed localization or wire-guided localization of nonpalpable invasive and in situ breast cancer: a randomized, multicenter, open-label trial. Ann Surg 2017; 266: 29-35.

Authors: Langhans L, Tvedskov T, Klausen T, Jensen M-J, Talman M-L, Vejborg I et al.

Scientific Surgery

Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017; 376: 2147-2159.

Authors: Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I et al.

Scientific Surgery

11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 2017; 389: 1195–1205.

Authors: Cameron D, Piccart-Gebhart M, Gelber RD, Procter M, Goldhirsch A, de Azambuja E et al.

Scientific Surgery

Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer. The SCALP randomized clinical trial. JAMA 2017; 317: 596-605.

Authors: Nangia J, Wang T, Osborne C, Niravath P, Otte K, Papish S et al.

Scientific Surgery

Telehealth system: a randomized controlled trial evaluating the impact of an internet-based exercise intervention on quality of life, pain, muscle strength, and fatigue in breast cancer survivors. Cancer 2016; 122: 3166-3174.

Authors: Galiano-Castillo N, Cantarero-Villaneuva I , Fernández-Lao C, Ariza-García A, Díaz-Rodríguez L, Del-Moral-Ávila R et al.

Scientific Surgery

Economic impact of routine cavity margins versus standard partial mastectomy in breast cancer patients: results of a randomized controlled trial. Ann Surg 2017; 265: 39-44.

Authors: Chagpar AB, Horowitz NR, Killelea BK, Tsangaris T, Longley P, Grizzle S et al.

Scientific Surgery

Prospective randomized controlled study to assess the value of a hemostatic and sealing agent for preventing seroma after axillary lymphadenectomy. J. Surg. Oncol 2016; 114: 423–427.

Authors: Piñero-Madrona A, Castellanos-Escrig G, Abrisqueta-Carrión J, Canteras-Jordana M

Scientific Surgery

Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer. A randomized clinical trial. JAMA 2016; 316: 1888-1896.

Authors: Foukakis T, von Minckwitz G, Bengtsson N-O, Brandberg Y, Wallberg B, for the Swedish Breast Cancer Group (SweBCG), the German Breast Group (GBG), and the Austrian Breast & Colorectal Cancer Study Group (ABCSG) et al.

Scientific Surgery

Lapatinib-related rash and breast cancer outcome in the ALTTO phase III randomized trial. J Natl Cancer Inst 2016; 108: djw037.

Authors: Sonnenblick A, de Azambuja E, Agbor-tarh D, Bradbury I, Campbell C, Huang Y et al.

Scientific Surgery

Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer: long-term follow-up (> 25 years) of the phase III SBII:2 pre trial. J Clin Oncol 2016; 34: 2232-2238.

Authors: Ekholm M, Bendahl P-O, Fernö M, Nordenskjöld B, Stål O, Rydén L et al.

Scientific Surgery

Adaptive randomization of Veliparib–Carboplatin treatment in breast cancer. N Engl J Med 2016; 375: 23-34.

Authors: Rugo HS, Olopade OI, DeMichele A, Yau C, van’t Veer LJ, Buxton MB et al.

Scientific Surgery

Adaptive randomization of Neratinib in early breast cancer. N Engl J Med 2016; 375: 11-22.

Authors: Park JW, Liu MC, Yee D, Yau C, van’t Veer LJ, Symmans F et al.

Older Entries

Newer Entries